Illinois Municipal Retirement Fund Grows Position in Zimmer Biomet Holdings, Inc. (NYSE:ZBH)

Illinois Municipal Retirement Fund boosted its stake in shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 29.1% during the 4th quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 93,460 shares of the medical equipment provider’s stock after purchasing an additional 21,046 shares during the period. Illinois Municipal Retirement Fund’s holdings in Zimmer Biomet were worth $9,872,000 at the end of the most recent quarter.

Several other large investors have also made changes to their positions in the business. Brown Financial Advisors lifted its position in shares of Zimmer Biomet by 3.4% in the fourth quarter. Brown Financial Advisors now owns 9,887 shares of the medical equipment provider’s stock valued at $1,044,000 after acquiring an additional 321 shares in the last quarter. Skylands Capital LLC lifted its position in shares of Zimmer Biomet by 87.5% in the fourth quarter. Skylands Capital LLC now owns 6,986 shares of the medical equipment provider’s stock valued at $738,000 after acquiring an additional 3,261 shares in the last quarter. New World Advisors LLC lifted its position in shares of Zimmer Biomet by 7.3% in the fourth quarter. New World Advisors LLC now owns 3,813 shares of the medical equipment provider’s stock valued at $403,000 after acquiring an additional 260 shares in the last quarter. South Dakota Investment Council lifted its position in shares of Zimmer Biomet by 266.6% in the fourth quarter. South Dakota Investment Council now owns 80,886 shares of the medical equipment provider’s stock valued at $8,544,000 after acquiring an additional 58,820 shares in the last quarter. Finally, World Equity Group Inc. purchased a new position in shares of Zimmer Biomet in the fourth quarter valued at about $256,000. 88.89% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

ZBH has been the topic of several research analyst reports. Stifel Nicolaus boosted their price objective on Zimmer Biomet from $130.00 to $138.00 and gave the company a “buy” rating in a research report on Thursday, January 23rd. JPMorgan Chase & Co. raised Zimmer Biomet from a “neutral” rating to an “overweight” rating and lifted their target price for the stock from $125.00 to $128.00 in a report on Tuesday, December 17th. Wells Fargo & Company lifted their target price on Zimmer Biomet from $110.00 to $117.00 and gave the stock an “equal weight” rating in a report on Thursday, October 31st. Needham & Company LLC reaffirmed a “hold” rating on shares of Zimmer Biomet in a report on Friday, February 7th. Finally, Raymond James reduced their target price on Zimmer Biomet from $126.00 to $119.00 and set an “outperform” rating on the stock in a report on Friday, February 7th. Two research analysts have rated the stock with a sell rating, eleven have assigned a hold rating and nine have given a buy rating to the company. According to data from MarketBeat.com, Zimmer Biomet currently has an average rating of “Hold” and an average target price of $124.15.

Zimmer Biomet Stock Up 1.5 %

Shares of NYSE:ZBH opened at $107.54 on Wednesday. Zimmer Biomet Holdings, Inc. has a 1 year low of $97.69 and a 1 year high of $133.90. The business has a 50 day simple moving average of $105.83 and a two-hundred day simple moving average of $107.44. The firm has a market capitalization of $21.41 billion, a PE ratio of 24.17, a price-to-earnings-growth ratio of 1.95 and a beta of 1.02. The company has a debt-to-equity ratio of 0.43, a current ratio of 1.91 and a quick ratio of 0.99.

Zimmer Biomet (NYSE:ZBH) last announced its earnings results on Thursday, February 6th. The medical equipment provider reported $2.31 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.30 by $0.01. Zimmer Biomet had a return on equity of 12.99% and a net margin of 11.77%. During the same quarter last year, the firm earned $2.20 earnings per share. On average, equities analysts predict that Zimmer Biomet Holdings, Inc. will post 8.22 EPS for the current year.

Zimmer Biomet Dividend Announcement

The firm also recently announced a quarterly dividend, which was paid on Friday, January 31st. Shareholders of record on Monday, December 30th were given a dividend of $0.24 per share. The ex-dividend date was Monday, December 30th. This represents a $0.96 annualized dividend and a dividend yield of 0.89%. Zimmer Biomet’s dividend payout ratio (DPR) is presently 21.57%.

Zimmer Biomet Company Profile

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.